Incepta launches cervical cancer vaccine

Incepta Vaccine Ltd has launched cervical cancer vaccine, Papilovax, for the first time in Bangladesh.

The country's first vaccine manufacturing company introduced the vaccine that protects against cervical cancer by preventing HPV virus responsible for cervical cancer, said a press statement of the Incepta.

Cervical cancer is the second leading cause of female cancer deaths in Bangladesh.

Every year, more than 10,000 women die of cervical cancer in the country and more than 50 million women are at risk of the disease. By giving this vaccine to all healthy women from nine to 45 years, Bangladesh can go a long way in eradicating cervical cancer. This vaccine will help meet the long-standing demand in the country, the press statement added.

Papilovax is also marketed in modern pre-filled syringes.

The full dose in pre-filled syringes are manufactured in aseptic environment and marketed at controlled temperature in fully sterile packaging. Direct administration of vaccine in pre-filled syringes is easy and does not require separate dosing. As a result, the vaccine can be administered more safely and easily at the correct dose.

doulot_akter@yahoo.com